FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217193711> ?p ?o ?g. }

• W3217193711 endingPage "175883592110582" @default.
• W3217193711 startingPage "175883592110582" @default.
• W3217193711 abstract "Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficacy and safety of nal-IRI + 5-FU/LV and the association of pre-emptive nal-IRI dosing with treatment outcomes in patients with PDAC. Methods: We retrospectively enrolled a total of 667 consecutive patients with PDAC who received nal-IRI plus 5-FU/LV treatment between August 2018 and November 2020 at 9 medical centers in Taiwan. Patients were allocated into groups according to pre-emptive nal-IRI dosing (⩾75%, 50–74%, <50%) for comparison of treatment efficacy and safety. Results: The median overall survival (OS) and time to treatment failure (TTF) were 5.9 months [95% confidence interval (CI), 5.3–6.5] and 2.8 months (95% CI, 2.6–3.0), respectively. The median OS was 6.5 months (95% CI, 5.7–6.7), 5.0 months (95% CI, 3.4–6.5), and 4.1 months (95% CI, 2.7–5.6), respectively, among the ⩾75%, 50–74%, and <50% pre-emptive nal-IRI dosing groups, whereas the median TTF of the three groups was 3.0 months (95% CI, 2.6–3.4), 2.6 months (95% CI, 2.3–2.9), and 1.9 months (95% CI, 1.6–2.2), respectively. Pre-emptive nal-IRI dosing <50% was an independent negative prognostic factor for OS and TTF in multivariate analyses. The most common severe adverse events were neutropenia (22.9%), anemia (21.1%), and hypokalemia (15.4%). Patients in the <50% pre-emptive nal-IRI dosing group had a significantly lower incidence of neutropenia and non-neutropenic infection than those in the other groups. Conclusion: Our results support the use of nal-IRI + 5-FU/LV as standard clinical practice for treating patients with PDAC based on this large population-based study. Our findings encourage physicians to provide adequate doses of nal-IRI in order to achieve better outcomes without compromising safety profiles." @default.
• W3217193711 created "2021-12-06" @default.
• W3217193711 creator A5001467169 @default.
• W3217193711 creator A5004548381 @default.
• W3217193711 creator A5018333718 @default.
• W3217193711 creator A5022533478 @default.
• W3217193711 creator A5025391355 @default.
• W3217193711 creator A5027198137 @default.
• W3217193711 creator A5027932918 @default.
• W3217193711 creator A5028067779 @default.
• W3217193711 creator A5028950420 @default.
• W3217193711 creator A5031833158 @default.
• W3217193711 creator A5037564480 @default.
• W3217193711 creator A5040496272 @default.
• W3217193711 creator A5042673919 @default.
• W3217193711 creator A5053209984 @default.
• W3217193711 creator A5067569205 @default.
• W3217193711 date "2021-01-01" @default.
• W3217193711 modified "2023-10-17" @default.
• W3217193711 title "Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study" @default.
• W3217193711 cites W1541934413 @default.
• W3217193711 cites W2023335214 @default.
• W3217193711 cites W2143953275 @default.
• W3217193711 cites W2151253787 @default.
• W3217193711 cites W2158134441 @default.
• W3217193711 cites W2158798157 @default.
• W3217193711 cites W2165480504 @default.
• W3217193711 cites W2187917981 @default.
• W3217193711 cites W2401329952 @default.
• W3217193711 cites W2518765238 @default.
• W3217193711 cites W2809815511 @default.
• W3217193711 cites W2901414145 @default.
• W3217193711 cites W2922273945 @default.
• W3217193711 cites W2936661484 @default.
• W3217193711 cites W2962542949 @default.
• W3217193711 cites W2966867342 @default.
• W3217193711 cites W2969586752 @default.
• W3217193711 cites W2972893160 @default.
• W3217193711 cites W2983117073 @default.
• W3217193711 cites W2988160220 @default.
• W3217193711 cites W2990401626 @default.
• W3217193711 cites W3005053253 @default.
• W3217193711 cites W3023520473 @default.
• W3217193711 cites W3091857196 @default.
• W3217193711 cites W3128646645 @default.
• W3217193711 cites W3128932138 @default.
• W3217193711 cites W3137626126 @default.
• W3217193711 cites W3143857301 @default.
• W3217193711 cites W4229719081 @default.
• W3217193711 doi "https://doi.org/10.1177/17588359211058255" @default.
• W3217193711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8606735" @default.
• W3217193711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34819998" @default.
• W3217193711 hasPublicationYear "2021" @default.
• W3217193711 type Work @default.
• W3217193711 sameAs 3217193711 @default.
• W3217193711 citedByCount "5" @default.
• W3217193711 countsByYear W32171937112022 @default.
• W3217193711 countsByYear W32171937112023 @default.
• W3217193711 crossrefType "journal-article" @default.
• W3217193711 hasAuthorship W3217193711A5001467169 @default.
• W3217193711 hasAuthorship W3217193711A5004548381 @default.
• W3217193711 hasAuthorship W3217193711A5018333718 @default.
• W3217193711 hasAuthorship W3217193711A5022533478 @default.
• W3217193711 hasAuthorship W3217193711A5025391355 @default.
• W3217193711 hasAuthorship W3217193711A5027198137 @default.
• W3217193711 hasAuthorship W3217193711A5027932918 @default.
• W3217193711 hasAuthorship W3217193711A5028067779 @default.
• W3217193711 hasAuthorship W3217193711A5028950420 @default.
• W3217193711 hasAuthorship W3217193711A5031833158 @default.
• W3217193711 hasAuthorship W3217193711A5037564480 @default.
• W3217193711 hasAuthorship W3217193711A5040496272 @default.
• W3217193711 hasAuthorship W3217193711A5042673919 @default.
• W3217193711 hasAuthorship W3217193711A5053209984 @default.
• W3217193711 hasAuthorship W3217193711A5067569205 @default.
• W3217193711 hasBestOaLocation W32171937111 @default.
• W3217193711 hasConcept C121608353 @default.
• W3217193711 hasConcept C126322002 @default.
• W3217193711 hasConcept C141071460 @default.
• W3217193711 hasConcept C2776694085 @default.
• W3217193711 hasConcept C2777288759 @default.
• W3217193711 hasConcept C2780258809 @default.
• W3217193711 hasConcept C2780259306 @default.
• W3217193711 hasConcept C2908647359 @default.
• W3217193711 hasConcept C44249647 @default.
• W3217193711 hasConcept C526805850 @default.
• W3217193711 hasConcept C71924100 @default.
• W3217193711 hasConcept C90924648 @default.
• W3217193711 hasConcept C99454951 @default.
• W3217193711 hasConceptScore W3217193711C121608353 @default.
• W3217193711 hasConceptScore W3217193711C126322002 @default.
• W3217193711 hasConceptScore W3217193711C141071460 @default.
• W3217193711 hasConceptScore W3217193711C2776694085 @default.
• W3217193711 hasConceptScore W3217193711C2777288759 @default.
• W3217193711 hasConceptScore W3217193711C2780258809 @default.
• W3217193711 hasConceptScore W3217193711C2780259306 @default.
• W3217193711 hasConceptScore W3217193711C2908647359 @default.
• W3217193711 hasConceptScore W3217193711C44249647 @default.
• W3217193711 hasConceptScore W3217193711C526805850 @default.

• next